Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos

Inward Investment
Return to: PBR Home | Inward Investment | News
Search Refinements

Inward Investment News

View news from other Pharmaceutical sectors:
16-30 of 421 results
Perrigo proposes to acquire Elan for $8.6bn
By PBR Staff Writer
Global healthcare products provider Perrigo Company and Elan have entered into a definitive agreement, under which the latter will be acquired by a new holding company in Ireland, New Perrigo, in a $8.6bn cash and stock transaction.
Inward Investment > News
GSK postpones plan to increase stake in Nigerian arm
By PBR Staff Writer
UK-based GlaxoSmithKline (GSK) has postponed plans to increase its stake from 46.4% to 75% in GlaxoSmithKline Consumer Nigeria (GSK Nigeria), proposed under a scheme of arrangement.
Inward Investment > News
Spectrum Pharmaceuticals to buy Talon Therapeutics
By PBR Staff Writer
Biotechnology company Spectrum Pharmaceuticals (SPPI) has entered into an agreement to acquire California-based biopharmaceutical firm Talon Therapeutics (TLON).
Inward Investment > News
Cipla completes acquisition of Cipla Medpro South Africa for $456.43m
By PBR Staff Writer
Indian based pharmaceutical company Cipla has completed the acquisition of Cipla Medpro South Africa for a consideration of ZAR4.507bn ($456.43m).
Inward Investment > News
Mitsubishi Tanabe Pharma plans to purchase Medicago for $357m
By PBR Staff Writer
Japanese Mitsubishi Tanabe Pharma (MTPC) has agreed to acquire Medicago, a biopharma company that develops vaccines, in a deal valued at nearly $357m.
Inward Investment > News
Acorda Therapeutics acquires Qutenza and NP-1998 from NeurogesX
By PBR Staff Writer
Acorda Therapeutics has acquired NeurogesX's Qutenza and NP-1998 in a bid to expand into the field of neuropathic pain management.
Inward Investment > News
TPG considers acquiring Envision Pharmaceutical
By PBR Staff Writer
Texas-based private-equity firm TPG Capital is said to be considering signing an agreement to acquire Envision Pharmaceutical Holdings, an Ohio-based pharmacy-benefits manager (PBM), for an undisclosed sum.
Inward Investment > News
Toksoz to sell Turkish generic drug maker Sanovel
By PBR Staff Writer
Toksoz Holding has decided to sell its Turkish generic drug maker, Sanovel, for an amount between $500m and $1bn.
Inward Investment > News
Pfizer, Novartis consider bidding to acquire Onyx Pharmaceuticals
By PBR Staff Writer
Pfizer and Novartis are considering participating in the bidding process to acquire Onyx Pharmaceuticals, a manufacturer of cancer medicines, following rejection of Amgen’s $$8.7bn buyout proposal.
Inward Investment > News
Paladin acquires Binotal in Latin America from Bayer
By PBR Staff Writer
Canadian specialty pharmaceutical company Paladin Labs has signed an agreement to acquire Binotal (ampicillin trihydrate) in Latin America from Bayer.
Inward Investment > News
Bioventus purchases exclusive rights to Pfizer's BMP portfolio
By PBR Staff Writer
Biologics company Bioventus has bought exclusive rights to Pfizer’s bone morphogenetic protein (BMP) portfolio of development programs and associated intellectual property, for an undisclosed sum.
Inward Investment > News
Sanofi, Novartis, GSK compete to acquire Elder Pharma's domestic formulations operations
By PBR Staff Writer
Global pharma companies Sanofi, Novartis and GSK are competing to acquire the domestic formulations business of debt-burdening Elder Pharmaceuticals.
Inward Investment > News
Kannalife Sciences, Biotech sign joint venture agreement
By PBR Staff Writer
Late stage bio-pharmaceutical and phyto-medical company Kannalife Sciences and Biotech have signed a 50/50 definitive joint venture agreement by creating South Park Ventures (SPV).
Inward Investment > News
Johnson & Johnson to buy Aragon Pharmaceuticals for $1bn
By PBR Staff Writer
US-based Johnson & Johnson has agreed to buy Aragon Pharmaceuticals, a discovery and development company focused on drugs to treat hormonally-driven cancers, for nearly $1bn.
Inward Investment > News
AstraZeneca agrees to acquire Pearl Therapeutics for $1.15bn
By PBR Staff Writer
AstraZeneca has agreed to purchase California-based respiratory medication developer, Pearl Therapeutics, in a deal with a total potential cost of up to $1.15bn.
Inward Investment > News
16-30 of 421 results